Myeloma Crowd Radio: Paul Richardson, MD, Dana Farber Cancer Institute

A new treatment called Selinexor was recently approved for highly relapsed multiple myeloma patients. Learn how experts like Dr. Paul Richardson of the Dana Farber Cancer Institute are using this new drug in their myeloma practice. Dr. Richardson will share how the drug works, when and how it should be used, potential side effects to watch out for and manage and why the new option is adding to patients' treatment choices.  Paul Richardson, MD is RJ Corman Professor of Medicine at Harvard Medical School and Attending Physician in the Division of Heamatologic Oncology in the Multiple Myeloma and Bone Marrow Transplant Service at the Dana Farber Cancer Institute. Dr. Richardson is the Clinical Program Leader and Director of Clinical Research for The Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute. Thank you to our episode sponsor, GlaxoSmithKlein.